Alexander GM, Swerdloff RS, Wang C, et al. Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. Hormones and Behavior 1998; 33(2):85-94.
Algarte-Genin M et al. Prevention of Prostate Cancer by Androgens: Experimental paradox or clinical reality? European Urology 46 (Sept 2004) 285-295
Araujo Ab et al Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clinical Endocrinol Metabolism 2004 Dec; 89(12):5920-6.
Arnlov J et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006 Aug 1; 145(3):176-84
Aydogan U, Aydogdu A, Akbulut H, Sonmez A, Yuksel S, Basaran Y, Uzun O, Bolu E, Saglam K. Increased frequency of anxiety, depression, quality of life and sexual life in young hypogonadotropic hypogonadal males and impacts of testosterone replacement therapy on these conditions. Endocr J. 2012 Aug 31.
Barrett-Connor E et al. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab 1999 Oct; 84(10):3681-5
Basaria et al. November 2001 Anabolic-Androgenic Steroid Therapy in the Treatment of Chronic Diseases. The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 11 5108-5117
Bhasin S et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006 Jun; 91(6):1995-2010.
Bhasin S. et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997 Feb; 82(2):407-13.
Bhasin S. The dose-dependent effects of testosterone on sexual function and on muscle mass and function. Mayo Clin Proc. 2000 Jan; 75 Suppl: S70-5
Boyanov MA et al. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003 Mar;6(1):1-7.
Burris A et al. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl 1992 Jul-Aug;13(4):297-304
Caminiti G et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009 Sep 1;54(10):919-27
Caretta N et al. Erectile dysfunction in aging men: testosterone role in therapeutic protocols. J Endocrinol Invest. 2005; 28 (11 Suppl Proceedings):108-11
Cassidenti D et al. Effects of sex steroids on skin 5 alpha-reductase activity in vitro Obstetrics & Gynecology 1991; 78:103-107
Channer KS, Jones TH Cardiovascular effects of testosterone: implications of the "male menopause"? Heart. 2003 Feb; 89(2):121-2.
Chen C et al. Cancer Epidemiol Biomarkers Prev. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. 2003 Dec; 12(12):1410-6.
Cooper CS et al. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men J Urol 1998 Feb; 159(2):441-3
Daniell HW et al. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002 Oct; 3(5):377-84.
Dimitrakakis C et al. Breast cancer incidence in women using testosterone in addition to usual hormone therapy. Menopause 11 (5) 2004
Edinger KL et al. Testosterone's anti-anxiety and analgesic effects may be due in part to actions of its 5alpha-reduced metabolites in the hippocampus. Psychoneuroendocrinology. 2005 Jun; 30(5):418-30
El-Sakka AI et al. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement. J Sex Med. 2005 Mar; 2(2):235-40,
Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies Endogenous Hormones and Prostate Cancer Collaborative Group. J Natl Cancer Inst 2008 100: 170-183
English KM et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 2000 Oct 17; 102(16):1906-11
Fink B et al. The 2nd-4th digit ratio (2D:4D) and neck circumference: implications for risk factors in coronary heart disease. Int J Obes (Lond). 2006 Apr; 30(4):711-4
Foresta C et al. Reduced Number of Circulating Endothelial Progenitor Cells in Hypogonadal Men. Journal of Clinical Endocrinology & Metabolism 91(11):4599–4602
Fukui, M et al. Diabetes Care 26:1869–1873, June, 2003
Gould DC, Kirby RS Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?Prostate Cancer Prostatic Dis. 2006;9(1):14-8
Gouras GK et al. Proc Natl Acad Sci U S A 2000 Feb 1; 97(3):1202-5
Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73:1016-1025.
Gunawardena, K et al. Testosterone is a potential augmentor of antioxidant induced apoptosis in human prostate cancer cells. Cancer Detect Prev. 2002; 26(2):105-13
Habib FK, et al. Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer. 2005 Mar 20; 114(2):190-4.
Hak, Elisabeth et al. Low Levels of Endogenous Androgens Increase the Risk of Atherosclerosis in Elderly Men: The Rotterdam Study. The Journal of Clinical Endocrinology & Metabolism Vol. 87, 2002, No. 8 3632-3639
Hatzoglou A. et al. Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo. (Journal of Clinical Endocrinology & Metabolism 2004, 10.1210/jc.2004-0801)
Hau M et al. Testosterone reduces responsiveness to nociceptive stimuli in a wild bird. Horm Behav. 2004 Aug; 46(2):165-70.
Hoffman MA. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000 Mar; 163(3):824-7
Hogervorst E et al. Low free testosterone is an independent risk factor for Alzheimer's disease. Exp Gerontol. 2004 Nov-Dec; 39(11-12):1633-9.
Holland J, Bandelow S, Hogervorst E. Testosterone levels and cognition in elderly men: a review. Maturitas. 2011;69:322-337.
Iczkowski, K. et al. The Dual 5 alpha reductase inhibitor dutasteride induces atrophic changes and decreases cancer volume in the human prostate. Urology 65:76-82, 2005
Jankowska EA. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA. 2009 May 13; 301(18):1892-901.
Janowsky JS. Thinking with your gonads: testosterone and cognition. Trends Cogn Sci. 2006 Feb;10(2):77-82.
Jeong, HJ et al. Inhibition of aromatase activity by flavinoids. ArchPharm Res. 1999 Jun; 22(3):309-12
Jones TH, Arver S, Behre HM, et al; TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34:828-837.
Daniel M Kelly and T Hugh Jones. “Testosterone: a vascular hormone in health and disease,” J Endocrology 217:3 R47–R71.
Keogh E Can a sexually dimorphic index of prenatal hormonal exposure be used to examine cold pressor pain perception in men and women? : Eur J Pain. 2006 Apr 4
Khaw KT, Barrett-Connor EJ. Blood pressure and endogenous testosterone in men: an inverse relationship. Hypertens. 1988 Apr; 6(4):329-32.
Khaw KT. et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men. Circulation. 2007; 116:2694-2701